{
    "nctId": "NCT00753415",
    "briefTitle": "A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)",
    "officialTitle": "A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma, Colon Carcinoma, Renal Cell Carcinoma, Bladder Carcinoma, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Number of Participants With Dose-Limiting Toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria Part A\n\n* Participant has one of the selected solid tumors with no distant metastases, and is more than 8 weeks from completion of definitive therapy with intention to cure. Selected Solid Tumors: Stage I to III non-small cell lung carcinoma (NSCLC); Stage III breast cancer; Stage IIB or III melanoma; Stage II or III upper gastrointestinal tract carcinoma (e.g., esophagus, stomach, gallbladder, pancreas); Stage III colon carcinoma; Stage II, III, or IV (M0 only) renal cell carcinoma; Stage II, III, or IV (M0 only) bladder carcinoma; clinically-localized prostate carcinoma\n* Participant has adequate organ function.\n* Female participant of childbearing potential has a negative serum pregnancy test within 3 days of study enrollment.\n\nExclusion Criteria Part A\n\n* Participant has known hypersensitivity to any component of study vaccine.\n* Participant has a history of clinically significant cardiac conditions, including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or New York Heart Association (NYHA) Class III or IV congestive heart failure. Participant must have no clinically significant electrocardiogram (ECG) abnormalities and not have a pacemaker or cardioverter/defibrillator implanted.\n* Participant has undergone splenectomy or has any history of autoimmune disorder.\n* Participant has received immunosuppressive treatment within 1 month prior to enrollment.\n* Participant has known acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections.\n* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of study entry.\n* Participant is pregnant or breastfeeding, or expecting to conceive at any time during the study or within 1 year after receiving the last vaccination.\n* Participant is known to be Human Immunodeficiency Virus (HIV)-seropositive.\n* Participant has known history of Hepatitis B or C or active Hepatitis A.\n* Participant has been vaccinated for any disease or for prophylaxis within 1 month prior to the first vaccination.\n* The participant has been diagnosed with Systemic Lupus Erythematosus (SLE)\n\nInclusion Criteria Part B\n\n* Participant must have completed their respective vaccination Treatment Group regimen for Part A of this study.\n* Participant must have completed a \u226512 week safety observation period prior to receiving their first V934-EP boost.\n\nExclusion Criteria Part B\n\n* Participant has new or metastatic tumor lesions since enrollment in Part A.\n* Participant has developed any significant cardiac conditions since enrollment in Part A including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or NYHA Class III or IV congestive heart failure.\n* Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.\n* Participant has received immunosuppressive treatment within 1 month prior to enrollment in Part B\n* Participant has developed any acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections\n* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of entry to Part B.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}